Selective PDE4 Inhibitors for Inflammatory Disease Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current PDE4 inhibitors for inflammatory diseases have adverse effects such as nausea and emesis due to non-specific isoform inhibition, and there is a need for compounds with a more favorable therapeutic window that retain anti-inflammatory efficacy.
Innovation Solution
Development of novel compounds with specific PDE4 inhibitory activity, represented by a formula that includes heterocyclic rings and various substituents, which can be used in pharmaceutical compositions for treating inflammatory and allergic diseases, autoimmune disorders, and dermatological conditions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If non-selective PDE4 inhibitors are used to treat inflammatory diseases, then anti-inflammatory efficacy is achieved, but adverse effects such as nausea and emesis occur due to non-specific isoform inhibition
Solution Approach 1:
The patent applies segmentation by designing compounds that selectively inhibit specific PDE4 isoforms (PDE4D and/or PDE4B) rather than all PDE4 isoforms. This selective inhibition segments the therapeutic effect from the adverse effects, allowing anti-inflammatory efficacy through PDE4B inhibition while avoiding nausea and emesis associated with PDE4D inhibition in the brain.
Solution Approach 2:
The patent applies local quality by creating compounds with selective affinity for specific PDE4 isoforms in specific tissues. The compounds exhibit different inhibitory properties in different locations (immune cells versus brain), achieving local therapeutic effect in inflammatory tissues while sparing the brain from adverse effects.
2Reliability
If selective PDE4 inhibitors are developed to reduce adverse effects, then therapeutic window is improved, but complexity of compound structure increases
Solution Approach 1:
The patent applies parameter changes by modifying specific structural parameters of the compounds (substituents at positions R1-R6, heterocyclic ring types, linkage groups) to tune the selectivity profile. By systematically varying these parameters, the patent achieves different degrees of isoform selectivity while maintaining reasonable structural complexity.
Solution Approach 2:
The patent applies composite materials by combining multiple structural elements (heterocyclic rings, substituent groups, linkage moieties) into composite molecular structures. These composite compounds achieve selective PDE4 isoform inhibition through the synergistic interaction of different structural components.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These compounds effectively inhibit PDE4 with reduced adverse effects, offering a broader therapeutic window for treating various inflammatory and dermatological conditions while maintaining anti-inflammatory benefits.
Implementation Method 1
Phosphodiesterases are enzymes that catalyse the hydrolysis of cyclic AMP and/or cyclic GMP in cells to 5-AMP and 5-GMP, respectively... Inhibition of PDE4 has therefore become an attractive target for the therapy of inflammatory diseases
Data Source
AI summary
The present invention relates to a compound according to formula I, wherein X, A, G, E, R1, R2, R3 are as shown herein; and pharmaceutically acceptable salts, hydrates, N- oxides or solvates hereof, said compounds are used as phoshodiesterase inhibitors in particular PDE4 inhibitors. The invention further relates to said compounds for use in therapy, to pharmaceutical compositions comprising said compounds, to methods of treating diseases, e.g. dermal diseases, with said compounds, and to the use of said compounds in the manufacture of medicaments.